Recommend Human Vaccines to your librarian for 2008. Download form here.

Sign up for TOC Alerts

Email this page

Print this page

Research Paper

Cost-Effectiveness of Adjuvanted Influenza Vaccination of Healthy Children 6 to 60 Months of Age

M. Marchetti, U.M. Kuehnel, G. Colombo, S. Esposito and N. Principi

This is an open-access article

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

This study estimated the health and economic outcomes of universal administration of a adjuvanted influenza vaccine to healthy pre-school children, as compared with current immunisation practice. A Markov model simulated a cohort of 3 million children and their households undergoing 5 influenza seasons. Assuming a vaccine uptake rate of 30%, at the current acquisition cost of €5.50 per vaccine dose influenza vaccination (two doses for unprimed children) of 6- to 60-month- (5-year) old children averted more than 1 million clinical influenza episodes and saved €63 million, from the perspective of the Italian society. From the perspective of the Italian health care service, influenza vaccination of 6- to 60- and of 6- to 24-month-old children cost €10,000 and €13,333 per quality-adjusted life year (QALY) saved, respectively. Administration of a adjuvanted influenza vaccine to children aged 6 to 60 months was highly cost-effective for the health care service and cost saving for the society.

Authors

M. Marchetti

IRCCS Policlinico S.Matteo; Pavia, Italy

U.M. Kuehnel

Berna Biotech; Bern, Switzerland

G. Colombo

Studi Analisi Valutazioni Economiche; Milan, Italy

S. Esposito

University of Milan; Milan, Italy

N. Principi

University of Milan; Milan, Italy

This is an open-access article

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.